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Introduction: Amyotrophic lateral sclerosis is a neurodegenerative disease characterized clinically by motor
symptoms including limb weakness, dysarthria, dysphagia, and respiratory compromise, and pathologically by
inclusions of transactive response DNA-binding protein 43 kDa (TDP-43). Patients with amyotrophic lateral sclerosis
also may demonstrate non-motor symptoms and signs of autonomic and energy dysfunction as hypermetabolism
and weight loss that suggest the possibility of pathology in the forebrain, including hypothalamus. However, this
region has received little investigation in amyotrophic lateral sclerosis. In this study, the frequency, topography, and
clinical associations of TDP-43 inclusion pathology in the basal forebrain and hypothalamus were examined in 33
patients with amyotrophic lateral sclerosis: 25 men and 8 women; mean age at death of 62.7 years, median disease
duration of 3.1 years (range of 1.3 to 9.8 years).
Results: TDP-43 pathology was present in 11 patients (33.3%), including components in both basal forebrain
(n= 10) and hypothalamus (n= 7). This pathology was associated with non-motor system TDP-43 pathology (Χ2= 17.5,
p= 0.00003) and bulbar symptoms at onset (Χ2= 4.04, p= 0.044), but not age or disease duration. Furthermore, TDP-43
pathology in the lateral hypothalamic area was associated with reduced body mass index (W= 11, p= 0.023).
Conclusions: This is the first systematic demonstration of pathologic involvement of the basal forebrain and
hypothalamus in amyotrophic lateral sclerosis. Furthermore, the findings suggest that involvement of the basal
forebrain and hypothalamus has significant phenotypic associations in amyotrophic lateral sclerosis, including site
of symptom onset, as well as deficits in energy metabolism with loss of body mass index.
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Amyotrophic lateral sclerosis (ALS) is a progressive
neurodegenerative disease characterized by loss of upper
and/or lower motor neurons, muscle wasting, and bulbar
symptoms (e.g., dysarthria, dysphagia) [1]. The pathologic
underpinnings of upper and lower motor neuron deficits
in ALS include neuronal loss and gliosis in large neurons
of “canonical” regions, including motor cortex, lamina IX
of the ventral horn of the spinal cord, and somatic motor
cranial nerve nuclei of the brainstem (XII, IX, and V) [2].* Correspondence: spowell@houstonmethodist.org
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unless otherwise stated.Detailed pathologic studies have also demonstrated
surprisingly widespread, non-motor pathology in some
ALS patients, typically in the form of ubiquinated cyto-
plasmic inclusions that are immunoreactive for transacti-
vating responsive sequence (TAR) DNA-binding protein
43 kDa, or TDP-43 [3]. Pathologic TDP-43 deposition is
presumed to induce neuronal dysfunction through the
cytoplasmic accumulation of toxic C-terminal TDP-43
fragments, or alternately, via the loss of constitutively
expressed nuclear TDP-43 that is critical in transcriptional
regulation and RNA processing [4]. As such, widespread
TDP-43 proteinopathy in “non-canonical” brain regions
(striatum, amygdala, non-frontal cortex, hippocampus) may
underlie multifocal neuronal dysfunction that contributesal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cognitive impairment with prominent frontal executive
dysfunction [5] and extrapyramidal signs [1]. Clinico-
pathologic studies confirming this presumption are rare,
but those that have been performed do support an asso-
ciation between extra-motor TDP-43 pathology and
extra-motor clinical findings [6].
Somewhat unique among extra-motor features in ALS
are alterations in energy metabolism [7], autonomic
function [8], and in some patients [9,10] and animal
models [11], involvement of the hypothalamic-pituitary
axis. Deficits in energy metabolism are well recognized
in ALS, with a paradoxical hypermetabolism occurring
in many patients that combines with dysphagia to result
in malnourishment and loss of body mass index (BMI)
[12]. Along with advanced age and bulbar onset at diag-
nosis [13], loss of more than one BMI unit over two
years is associated with a significantly shorter survival
and more rapid disease progression [7]. Deficits in en-
ergy metabolism and autonomic function in ALS suggest
the possibility of hypothalamic dysfunction, which may
be indicated by pathologic TDP-43 deposition. This is
further supported by evidence from Alzheimer disease
[14], argyrophilic grain disease [15], Lewy body spectrum
diseases [16], and multiple system atrophy [17], in which
neurons of the hypothalamic region and adjacent basal
forebrain are susceptible to neurodegenerative disease-
associated cellular injury [18]. Although similar fore-
brain/hypothalamic pathology may be present in ALS
and contribute to the extra-motor features of the disease
[1,8], this has yet to be systematically investigated.
This study was carried out to determine whether the
basal forebrain and hypothalamus are pathologically
involved in ALS. We hypothesized that pathologic TDP-
43 inclusions would be identified in a subset of ALS
patients given the deficits in energy metabolism and
autonomic function in ALS and frequent involvement of
these regions in other neurodegenerative diseases. The
frequency and topography of TDP-43 inclusions were
examined in 33 ALS patients within these structures.
Pathology in this region also was examined with respect
to disease duration, the extent of TDP-43 proteinopathy,
last available BMI, which is an indirect measure of en-
ergy metabolism, and patient age, since TDP-43 path-
ology may be seen in older patients without ALS [19].
Materials and methods
Pathologic materials were reviewed for 56 consecutive
patients with clinically diagnosed and pathologically
confirmed ALS. Archival materials were screened for
representative portions of basal forebrain and hypothal-
amus (defined further below). Thirty-three patients were
selected for study based on the presence of appropriate
anatomic regions.Autopsy and clinical data
Patient autopsies performed at the Houston Methodist
Hospital included sections from all cerebral lobes, basal
ganglia, thalamus, amygdala, hippocampus, midbrain, pons,
medulla, cerebellum, spinal cord and pituitary. Immunos-
tains performed on the majority of cases included tau
(Dako, polyclonal, 1:40,000 dilution), beta-amyloid (Dako,
clone 6 F/3D, 1:20 dilution), alpha-synuclein (EMD
Millipore, clone AB5038, rabbit polyclonal, 1:4000), and
TDP-43 (ProteinTech, 10782-2-AP, polyclonal antibody,
1:200). An immunostain for ubiquitin (Dako, polyclonal,
1:500 dilution) also was performed on several archived
cases. Immunostaining was performed on brain tissue
that was fixed in 20% formalin for a minimum of seven
days following brain removal. Sections were further
fixed in 10% formalin until processing and embedding.
Formalin fixed paraffin embedded tissue was sectioned
at 4 microns, mounted on plus coated slides and dried at
60°C. Immunostaining was performed on the BenchMark
ULTRA© platform (Ventana Medical Systems, Inc., Tucson,
AZ) with appropriate positive and negative controls.
Neuropathologists at Houston Methodist Hospital (H.T.,
S.Z.P.) utilized established criteria to assess Alzheimer
disease (AD) neuropathologic changes, including neuro-
fibrillary changes [20,21] and parenchymal amyloid
[22,23], Lewy body pathology [16], ALS pathology [24],
cerebral amyloid angiopathy (CAA), and vascular brain
injury (VBI). Clinical variables recorded included date
of symptom onset and date of death (disease duration
calculated as the difference between these), presenting
symptoms, clinical dementia, and family history of ALS.
Body mass index (BMI) was also recorded for patients
where this data was available within ≤ 24 months of
death (29 of 33 patients, median interval of 3.6 months
between measurement and death, interquartile range
0.8-8.6 months). These studies were carried out with
the approval of the Institutional Review Board at Houston
Methodist Hospital (IRB-2-0114-0013).
Identification of basal forebrain and hypothalamic
components
Basal forebrain components were defined on H&E and
TDP-43 stains and included ventral pallidum (VP), ven-
tral striatum and small granule cell islands (VS/Is), the
bed nucleus of the stria terminalis (BNST), lateral septal
area (LSA), and other neurons of the substantia innomi-
nata (SI). VP included large pallidal neurons ventral to
fibers of the anterior commissure [25]. SI included
medium-sized neurons, which did not always respect
anatomic borders, as well as magnocellular neurons
(e.g., nucleus of the diagonal band, nucleus basalis) [26].
VS/Is included medium-sized striatal neurons and islands
of small granule cells, located within or ventromedial
to VS, as well as within SI and VP in the region of the
Figure 1 Schematic demonstrating anatomic structures
investigated in the basal forebrain (A), mid-hypothalamus
(tuberal level) (B), and caudal hypothalamus (mammillary
level) (C) (see Materials and methods for detail). To the left of
each schematic, grayscale renderings of TDP-43-stained sections of
study patients are shown for comparison. In A, the continuity of
rostral/chiasmatic hypothalamus and basal forebrain, as discussed
in the text, is shown on both the histologic image (which also includes
the optic chiasm) and on the schematic (POA). Abbreviations not defined
in text: ac – anterior commissure, cc – crus cerebri, fmp – fasciculus
mammillaris princeps (mammillary efferents), fx – fornix, GPe/i – external/
internal segments of the globus pallidus, FPut – fundus of the putamen,
ic – internal capsule, LV – lateral ventricle, mfb - medial forebrain bundle,
mmt – mammillothalamic tract, mmtg – mammillotegmental tract,
ot – optic tract, 3v – third ventricle.
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small granule cells comprising “Islands of Calleja” versus
“interface” islands [28] is not clear, we adopted the
descriptive term used here. BNST was defined as the
wedge-shaped group of medium-sized neurons dorsal to
anterior commissure, medial to the internal capsule,
ventral to caudate nucleus, and lateral to the LSA [26,29].
Hypothalamic nuclear groups were defined on H&E
and TDP-43 stains by cytologic characteristics and relative
position using standard anatomic references [18,29-32].
Hypothalamic nuclei often merge with surrounding
nuclear groups without distinct borders [29,30], due in
part to inherent anatomic variability in the region [31].
Therefore, neuronal groups with similar positional and
cytologic characteristics were grouped for recording of
TDP-43 pathology. Nuclei examined at the chiasmatic
level included discrete magnocellular neurosecretory neu-
rons of the supraoptic (SON) and paraventricular (PaV)
nuclei [30]. At the chiasmatic level, TDP-43 pathology in
small- to medium-sized neurons of the preoptic area
(POA) [31] (including “hypothalamic” or “chiasmatic gray”
in some sources [18,30]) was recorded. At the tuberal and
mammillary levels, neurons assessed included ventrally
located, medium- to large-sized neurons of the medial
mammillary nucleus, lateral tuberal nucleus (in some
sections), and ventral portion of the tuberomammillary
nucleus (MN/LTN/TMN). Likewise, large neurons lateral
to the fornix and mammillothalamic tract were recorded
as lateral hypothalamic area, which merges with the dorsal
portion of the tuberomammillary nucleus (LHA/TMN)
[29,32]. At the tuberal level, inclusions were also recorded
in diffuse, small- to medium-sized neurons adjacent to
the third ventricle, including those of the ventromedial
hypothalamus (PVL/TBL/VMH). At the mammillary level,
medial to fiber bundles of the mammillothalamic tract,
medium- to large-sized periventricular neurons were
recorded as posterior hypothalamic area (PHA) [31,32].
These anatomic regions are shown in schematic form
for basal forebrain (Figure 1A), including LSA and
BNST, and hypothalamus at the caudal chiasmatic/
tuberal level (Figure 1B), and level of the mammillary
bodies (Figure 1C).
Assessment of TDP-43 pathology
Two authors (M.D.C., H.T.) independently rated TDP-
43 pathology in the aforementioned areas. The location
of pathologic TDP-43 inclusions was recorded and clas-
sified by morphologic sub-type as follows: neuronal
cytoplasmic (NCI), neuronal intranuclear (NNI), glial
cytoplasmic (GCI), and dystrophic neurites. For cases
with TDP-43 inclusion pathology, quantitative measures
were performed in the area of greatest hypothalamic
pathology (or basal forebrain in cases without hypothal-
amic pathology). For these cases, any cellular TDP-43
Table 1 Demographics and non-ALS pathology in 33
patients
Average age at death (years) 62.7 (s = 9.09)
Male/Female n = 25/n = 8
Median duration (years) 3.1 (interquartile range, 2.2-4.8)
Brain weight (grams) 1348.6 (s = 156.97)
Any neurofibrillary pathology n = 24
Any parenchymal amyloid n = 9
Thal stage≥ II n = 7
Braak stage ≥ III1 n = 4
CERAD ≥ “moderate” n = 2
CAA present2 n = 6
VBI present3 n = 3
LB pathology n = 0
Abbreviations: CAA cerebral amyloid angiopathy, CERAD Consortium to
Establish a Registry for Alzheimer Disease (see text), LB Lewy body, VBI
vascular brain injury.
Notes: 1One patient with Braak stage III had co-existing argyrophilic grain
disease (AGD). 2CAA was diffuse in only 1 of these 6 patients. 3VBI was present
in one patient each as remote infarct (left temporal lobe), hippocampal microin-
farct, and acute/subacute hemispheric infarct.
Cykowski et al. Acta Neuropathologica Communications  (2014) 2:171 Page 4 of 11inclusions (NCI, GCI) were recorded within three con-
secutive high-power microscopic fields (HPF) at 400 ×
magnification (0.19625 mm2 per HPF). Global TDP-43
pathologic burden was classified as canonical (brainstem,
spinal cord, motor cortex) or non-canonical (canonical
regions plus dorsal striatum, thalamus, non-frontal iso-
cortex, and mesial temporal lobe).
Statistical analysis
Two-sided Mann–Whitney (Wilcoxon rank sum) test-
ing was used to determine whether: (a) disease duration
significantly differed between patients with and without
basal forebrain/hypothalamic pathology, (b) disease dur-
ation significantly differed between patients with canonical
and non-canonical TDP-43 pathology, (c) BMI signifi-
cantly differed in patients with and without basal fore-
brain/hypothalamic pathology, (d) BMI significantly
differed in patients with and without LHA pathology,
and (e) age at death significantly differed between those
with and without basal forebrain/hypothalamic TDP-43
pathology. Chi-squared (Χ2) testing was used to deter-
mine whether basal forebrain/hypothalamic pathology
was associated with (a) non-canonical TDP-43 path-
ology and (b) bulbar/respiratory onset.
Results
Clinical characteristics and autopsy findings
Table 1 lists demographic information for 33 ALS pa-
tients. Presenting symptoms included unilateral extremity
weakness with or without muscle fasciculations (46.4%),
bulbar symptoms such as slurred speech, shortness of
breath, dysarthria, and difficulty swallowing (25.0%),
muscle cramps (17.8%), bilateral extremity or general-
ized weakness with/without fasciculations (17.8%), falls
(10.7%), and foot drop (3.5%). One patient showed clin-
ically evident cognitive impairment with episodes of
disorientation and word-finding difficulties. In two pa-
tients with a family history of ALS the genes implicated
were not known (one of the two had SOD1, TARDBP,
ANG, FUS, FIG4 studied) though both patients had ALS
TDP-43 pathology outside of the hypothalamic region.
At autopsy, all patients had pathologically confirmed
ALS. Table 1 lists non-ALS brain pathologies identified,
including AD neuropathologic changes, CAA and VBI.
TDP-43 inclusion pathology in basal forebrain and
hypothalamus
Pathology in basal forebrain and hypothalamus was
present in 11 of 33 cases (33.3%). This included compo-
nents of basal forebrain in 10 patients: VS/Is, n = 9 of 26
patients with the structure present; BNSTL, n = 8 of 21; SI
neurons, n = 6 of 28; typically in medium-sized neurons
with magnocellular neurons having filamentous/skein-like
inclusions in only two cases; LSA, n = 2 of 15; and, VP,n = 1 of 21. This also included components of the hypo-
thalamus in 7 patients, including LHA/TMH, n = 5 of 28;
PHA, n = 3 of 24; MB/LTN/TMN, n = 6 of 19; PVN/POA,
n = 2 of 16; and PVL/TBL/VMH, n = 4 of 10. The SON
was not involved (n = 13). Representative findings are
demonstrated for basal forebrain and hypothalamus in
Figures 2 and 3, respectively.
Neuronal inclusions were uniformly cytoplasmic (NCIs),
while intranuclear inclusions were not identified. The
density of TDP-43 cellular inclusions varied between
1/three HPFs to 72/three HPFs: the average number of
inclusions was 8.42 (sd = 18.75), with a per field average
of 2.8 inclusions. NCI morphology consisted of granu-
lar preinclusions (e.g., Figure 3F), dense perinuclear
and cytoplasmic inclusions that were crescent-shaped
or globoid (e.g., Figure 2D and F, Figure 3B and E), and
rarely, densely staining filamentous and skein-like in-
clusions (Figure 2B and inset of Figure 3B). GCIs were
frequently identified in patients with NCIs in basal
forebrain and hypothalamus. GCIs could be distin-
guished from small neurons with NCIs in the forebrain
on the basis of cell size (see inset of Figure 2H for com-
parison). Thick, tortuous TDP-43 positive neurites
were occasionally seen (see bottom left of Figure 2H)
but were uncommon.
For all cases positive for TDP-43 pathology in the
regions under investigation (n = 11), two authors (MDC,
SZP) performed a post-hoc rating of gliosis (on H&E
stain) as absent, mild, moderate, or severe. One patient
had mild gliosis in the preoptic area of the hypothalamus
and this same patient had mild to focally moderate gliosis
in basal forebrain (most apparent in the BNST). Three
Figure 2 Basal forebrain pathology in ALS including TDP-43 immunostain examples from six different ALS patients. (A) Representative
low-power histologic section (LFB/PAS-hematoxylin) demonstrating magnocellular neurons within nucleus of the diagnonal band (NDB) (pial surface
at bottom left of image). (B) Skein-like TDP-43 inclusion within the horizontal limb of the NDB (400 ×, scale bar is 20 microns). (C) Representative
lower-power histologic section demonstrating the location of the bed nucleus of the stria terminalis (BNST) and adjacent lateral septal area (LSA)
at the level of the internal capsule (ic), anterior commissure (ac), and lateral ventricle (lv) (compare to Figure 1A). (D) Numerous NCIs within the
BNST (highlighted by black arrows) (200 ×, scale bar is 50 microns). (E) Low-power LFB/PAS-H histologic section demonstrating ventral striatum
(Vs/Is) including clusters or “islands” of small neurons (bottom center of image). (F) Numerous NCIs in small neurons of the VS/Is (400 ×). (G,H)
Medium-sized neurons of “substantia innominata” with frequent TDP-43 NCIs and neurities (bottom left of H). These cells could not be attributed to a
specific nuclear group or region on H&E stain (see text) (400 ×) (H, inset). A glial cytoplasmic inclusion (at 400 ×) is shown for comparison of cell size
with small- and medium-sized neurons with NCIs in panels D, F, G, and H.
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typically most apparent medially including within BNST. A
fifth patient had moderate gliosis more diffusely throughout
basal forebrain ventral to the anterior commissure (this pa-
tient had 63 TDP-43 cellular inclusions/three HPFs). Neur-
onal loss was not evident on H&E stain in these patients.
Extent of TDP-43 pathology
ALS pathology in typical (canonical) regions was char-
acterized by neuronal loss and gliosis with ubiquitinated
or TDP-43 immunoreactive inclusions. Brain regions
implicated included spinal cord (n = 33), brainstem
motor nuclei (n = 27), other brainstem nuclei (n = 17),
and agranular frontal cortex (n = 22). Seventeen of 33
patients had pathologic involvement limited to these
canonical regions. The remaining 16 patients had path-
ology in these regions plus non-canonical pathology, i.e.
additional involvement of hippocampus (n = 11), amygdala
(n = 11), non-frontal isocortex (n = 9), dorsal striatum
(n = 10), and thalamus (n = 8).
Association of pathology in basal forebrain/hypothalamus
with non-canonical pathology
TDP-43 pathology in basal forebrain/hypothalamus was
seen only with non-canonical pathology (Χ2 = 17.5, p =
0.00003). Moreover, all but one case with hypothalamicTDP-43 pathology occurred with concurrent basal fore-
brain pathology. In contrast, sparse basal forebrain
pathology (range of 2–3 NCIs in three HPFs) occurred in
three cases without hypothalamic pathology. An additional
case with dense basal forebrain pathology (63 NCIs in
three HPFs) did not have hypothalamic tissue available
for study.
Association of pathology with clinical presentation
There was a significant association between bulbar onset
symptoms and basal forebrain/hypothalamic pathology
(Χ2 = 4.04, p = 0.044) with 71.4% of all patients having
bulbar symptoms at disease onset demonstrating this
pathology (compared to 28.6% of patients without bulbar
symptoms at onset).
Association of pathology with disease duration and
patient age
For patients with complete data on disease duration
(n = 30), this parameter did not significantly differ between
patients with basal forebrain/hypothalamic TDP-43 path-
ology (median of 3.26 years, interquartile range, 2.5-5.3)
and without (median of 3.1 years, interquartile range,
2.1-3.5) (W = 90, p = 0.55). Likewise, the density of
TDP-43 inclusions was not correlated to disease dur-
ation (Spearman rho = 0.18, p = 0.33). Disease duration
Figure 3 Hypothalamic pathology in ALS including TDP-43 immunostain examples from six different ALS patients (five pathologic, one
normal). (A) Representative LFB/PAS-hematoxylin-stained section at intermediate magnification demonstrating large neurons and myelinated
fiber bundle within the lateral hypothalamic area (LHA). (B) NCIs in the LHA of two different patients (both at 400 ×, scale bar is 20 microns),
including a patient with dense, filamentous inclusions (inset). (C) Representative LFB/PAS-hematoxylin-stained section at low power magnification
demonstrating the medial mammillary nucleus (MMN) of the mammillary body and the fasciculus mammillaris princeps (fmp), representing the
common origin of the mammillotegmental and mammillothalamic tracts. (D) Numerous NCIs (black arrows) and rare GCIs (white arrow) within the
MMN (200 ×, scale bar is 50 microns). (E) NCIs within the lateral tuberal nucleus (200 ×) and NCIs, including many granular preinclusions, within
ventromedial hypothalamus at the tuberal level (400 ×) (F). (G) Characteristic low power magnification appearance on LFB/PAS-hematoxylin-stained
section of large, loosely cohesive neurons in the supraoptic nucleus (SON) overlying the optic tract (opt). (H) SON neurons (seen here at 100 ×, scale
bar is 100 microns) did not demonstrate TDP-43 pathology and inclusions were likewise very infrequent in the large, secretory neurons of the
paraventricular nucleus (not shown).
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canonical (median of 3.0 years, interquartile range, 2.4-
4.7) and canonical TDP-43 pathology (median of 3.1 years,
interquartile range, 2.1-4.9) (W = 109, p = 0.92). Patient
age at death did not significantly differ between those
with (mean = 64.1 years, sd = 11.33 years) and without
(mean = 62.0 years, sd = 7.96 years) TDP-43 pathology
in basal forebrain/hypothalamus (W = 95, p = 0.33).
Association of basal forebrain and hypothalamic
pathology with BMI
BMI did not significantly differ between patients with
(median BMI of 21.9 kg/m2, interquartile range, 20.8-
28.2) and without (median of 26.2 kg/m2, interquartile
range, 23.4-28.0) any basal forebrain and/or hypothalamic
pathology (W = 82, p = 0.57). BMI did significantly differ,
however, between patients with (median of 20.9 kg/m2,
interquartile range, 20.7-21.3) and without (median of
27.1 kg/m2, interquartile range, 24.1-28.2) pathology in
the LHA specifically (W = 11, p = 0.023) (see Figure 4).
Both initial BMI (at a median interval of 8.9 months from
symptom onset) and last recorded BMI (3.6 months from
measurement until patient death, see Materials and
methods for detail) were available in 25 patients. The
percent differences between initial and last recorded BMI(positive percent difference values indicating loss of BMI
points) were 6.0%, 8.3%, and 26.6% for patients with no
forebrain/hypothalamic TDP-43 pathology, any forebrain/
hypothalamic pathology, and LHA/TMN region TDP-43
pathology, respectively.
Discussion
Patients with ALS may experience a variety of extra-motor
symptoms that have been referred to as “ALS-plus” syn-
dromes, but that may simply represent a more complete
spectrum of the disease [1]. These signs and symptoms
include energy metabolism deficits [12], subclinical auto-
nomic nervous system dysfunction [8], and frontal execu-
tive dysfunction manifesting as cognitive impairment in
up to 51% of patients [5].
This study is the first to systematically investigate
whether TDP-43 pathology in the basal forebrain and
hypothalamus of ALS patients might contribute to these
extra-motor symptoms, given the important roles of these
regions in cognition, energy metabolism and thermore-
gulation, endocrine function, feeding behaviors, and
autonomic responses [25,33,34]. TDP-43 pathology was
identified in this region in one-third of patients and
stereotypic involvement of certain structures was found
(e.g., VS/Is, BNST, medium-sized neurons of SI, LHA/TMN,
Figure 4 Boxplots of BMI relative to involvement of any region
in the basal forebrain and/or hypothalamus (left) versus LHA
(right) for patients with a BMI measure within ≤ 24 months the
time of death (median interval of 3.6 months). Plots represent
BMI for basal forebrain/hypothalamus (n = 29; 19 patients without
TDP-43 pathology and 10 with inclusion pathology) and for patients
with the LHA sampled (n = 25; 21 patients without TDP-43 pathology
and 4 with inclusion pathology). There was no significant difference in
BMI for patients with and without TDP-43 pathology in any component
of forebrain/hypothalamus (left). For the LHA, a significant difference
in BMI was identified between patients with and without TDP-43
pathology (p = 0.02). Boxplot prepared in R (R Foundation for Statistical
Computing, Vienna, Austria, 2014).
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(VP, SON, PVN). Pathology in this region was seen only in
the context of other non-canonical TDP-43, including within
dorsal striatum, thalamus, non-frontal cortex, hippocampus
(each of these regions involved in seven patients) and
amygdala (in eight patients) (see Figure 5). No patients
with isolated motor neuron and hypothalamic pathology
were identified, and with a single exception, hypothal-
amic pathology appeared to follow basal forebrain path-
ology. As such, the pathology identified here is best
placed in context of the progressive, widespread TDP-
43 proteinopathy recently characterized as stage III and
stage IV for ALS TDP-43 pathology [35].
We also tested whether AD neuropathology [36] or
aging [19] influenced the TDP-43 pathology identified.
The lack of advanced AD neuropathology (see Table 1)
and demonstration that age did not influence TDP-43
pathology in the cohort suggests this is not the case and
that these findings are in indeed within the spectrum of
ALS pathology.
The location of forebrain and hypothalamic pathology in
ALS
The finding of basal forebrain and hypothalamic pathology
in ALS patients is consistent with earlier observations. Onerecent study of pathologic staging in ALS identified the
heaviest burden of subcortical TDP-43 pathology in the VS
[35]. We similarly identified NCIs in VS, but also within
the associated small granule cell islands adjacent to VS and
within the area of the olfactory tubercle (Figure 2E, F).
Though their role is poorly understood, these small neu-
rons are thought to receive afferent input from serotoner-
gic and catecholaminergic cells of the brainstem and may
have projections to dendrites of adjacent striatal cells [37].
NCIs also were identified in the LSA (two patients) with
both of these patients having filamentous or skein-like in-
clusions in magnocellular neurons of basal forebrain (nu-
cleus of the diagonal band). This relationship is intriguing
as a “hippocampal-septal area-diagonal band” circuit has
been proposed as a structural subunit of basal forebrain
organization [33] and raises the question of whether the
pathology identified may reflect underlying structural and
functional homologies between neuronal groups.
TDP-43 pathology was also identified in medium-
sized, nondescript neurons of the SI that could not be at-
tributed to VP, VS/Is, or magnocellular neuron groups
(see Figure 2H). The possibility that these cells represent
extensions of amygdala into the basal forebrain [33]
would be consistent with the frequent involvement of
amygdala in ALS patients, as well as with frequent con-
current pathologic involvement of the BNST (also iden-
tified here), which itself is a portion of the “extended”
amygdala [38]. TDP-43 pathology in amygdala and ex-
tended amygdala may in part underlie behavioral alter-
ations in some ALS patients that are usually present in
non-ALS patients with bilateral amygdala damage [39].
There are fewer examples of pathologic involvement of
the hypothalamus in the ALS literature. Takahashi and
colleagues reported a single case of ALS with cell loss and
gliosis in cortical and subcortical neurons, including
within the MB [40]. A recent study from Mayo Clinic
Jacksonville identified TDP-43 NCIs in the hypothalamus
of ALS and FTLD/ALS patients (more frequently in the
latter group) [41]. We identified neuronal cytoplasmic
TDP-43 inclusions in five patients, most frequently within
neurons of the LHA (see Figure 3B), as well as within neu-
rons of MB and adjacent tuberal nuclei. Neurons of hypo-
thalamus, particularly the LHA, may receive both neural
and neurohormonal input to regulate a number of func-
tions including metabolic rate, feeding behavior, and auto-
nomic function [34]. Further studies are also warranted to
examine affected nuclei using both TDP-43 and proteins
marking neuronal sub-populations (e.g., orexin/hypocre-
tin, alpha-melanocyte stimulating hormone).
Potential implications of forebrain and hypothalamic
pathology in ALS
The finding of significantly reduced BMI in patients with
LHA pathology is intriguing (see Figures 3 and 4) and
Figure 5 Canonical and non-canonical pathology outside forebrain/hypothalamus in an ALS patient with forebrain/hypothalamic
TDP-43 pathology, bulbar symptom onset, and survival of 29.8 months. Pathology in canonical regions, such as lower motor neurons of
the hypoglossal nucleus (A), was characterized by neuronal loss, gliosis (white arrows), rarefaction of neuropil, and on TDP-43 immunostain (B),
pleomorphic inclusions. Non-canonical TDP-43 pathology was seen in the deep layers of entorhinal cortex (C, D; black arrows indicate neuronal
cytoplasmic inclusions in all panels), basolateral amygdala immediately overlying the temporal horn of the lateral ventricle (E, F), and hippocampal
sector CA1 (G). This patient also demonstrated glial cytoplasmic inclusions (H, white arrows). All images taken at 200× (scale bar of 50 microns as
shown in panel A applies to all panels).
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contribute to metabolic disturbances and weight loss in
ALS, in addition to increased muscle work, possible
mitochondrial defects [12], and dysphagia/bulbar symp-
toms [42]. Patients with ALS have a paradoxical eleva-
tion in resting energy expenditure (~10% greater than
matched controls), which is surprising given their loss
of fat-free mass (itself an important determinant of
basal metabolic rate) [43]. The pathophysiologic bases
for this finding remain unexplained but may relate to
nutritional status, which is prognostically important [13].
However, several caveats require mention. First, rare
patients without forebrain and hypothalamic pathology
had a relatively low last available BMI (see Figure 4),
which indicates the mechanisms underlying metabolic
alterations and BMI loss in ALS are multiple and not
entirely understood. Second, a significant association of
bulbar onset of symptoms and forebrain/hypothalamic
pathology was identified. Even limb-onset patients often
experience bulbar symptoms late in their disease course.
Aggressive clinical interventions are performed in such
patients to counteract the detrimental effects of dysphagia
on BMI [42]; still, the exact contributions of pathologic
and clinical factors on weight loss are difficult to estimate.
An additional question is whether BMI changes in ALS
patients are the result of extensive TDP-43 proteinopa-
thy or the result of neuronal dysfunction in specific
populations. We had identified forebrain and hypothalamicpathology only in patients with widespread TDP-43
inclusions (e.g., Figure 5). BMI did not significantly
differ when any forebrain/hypothalamic pathology was
considered (Figure 4, left box plots), which suggests the
LHA region pathology may be important in this respect.
However, this does not exclude the possibility that
TDP-43 pathology in other brain regions influences
metabolic rate and BMI in ALS.
There likely are several other clinical implications for
patients with hypothalamic pathology in ALS since this
structure subserves affective behaviors, autonomic func-
tion, sleep-wake cycles, thermoregulation, feeding and
reproductive behaviors, water balance, and endocrine
function [29-31]. Clinical studies of hypothalamic func-
tion in ALS are rare so the clinical correlates of the
pathology are difficult to estimate. Nonetheless, reduced
growth hormone has been reported in up to 52% of ALS
patients [10]. Likewise, inappropriate secretion of anti-
diuretic hormone has also been documented [9], which
raises the possibility of hypothalamic neuronal dysfunc-
tion (e.g., osmoreceptors). Significant pathology in the
LHA is also likely to impair the ascending arousal sys-
tem in ALS patients. LHA and forebrain nuclei receive
afferents from monoamenergic neurons in the brainstem
(e.g., locus ceruleus), among other sites, and have a pro-
found influence on wakefulness via projections to cerebral
cortex [44]. Ultimately, any anatomic focus of significant
hypothalamic pathology is likely to have multiple effects
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reflected in widespread connections to hippocampus,
corticomedial and basolateral amygdala, basal ganglia, and
midbrain tegmentum and reticular formation [29,31,32],
as well as thalamus, dorsal medulla, neurohypophysis, pre-
ganglionic neurons of spinal cord [29], and isocortex
[31,32,34]. The implications of TDP-43 pathology in this
region are further complicated by the fact that basal
forebrain and hypothalamic neurons are in anatomic
contiguity (e.g., septal area, diagnonal band, and rostral
hypothalamus) [30], are interconnected (e.g., via medial
forebrain bundle), and for hypothalamus, have inter-
nuclear short fiber connections [32].
Extent of TDP-43 pathology and disease duration in ALS
An important finding of this study is an asynchrony be-
tween disease extent and clinically determined disease
duration. Similar results have been observed in other
autopsy series [35] and in reports of patients with rapid
disease progression yet widespread TDP-43 pathology
[45]. These findings support a model of non-linear propa-
gation of neuropathology in this disease that is not time-
dependent [46]. As such, pathology in ALS appears
distinct from AD and Lewy body spectrum-diseases, in
which extent and intensity of the tauopathy and alpha-
synucleinopathy, respectively, are presumed to be modi-
fied by disease duration with a spectrum of pre-clinical
pathologic stages [16,20].
Three patients in this study, for example, had un-
usually long survival (>6.5 years), and their pathology
was limited to canonical regions (spinal cord, brainstem,
agranular frontal cortex). Conversely, three different
patients with disease durations less than 2.5 years had
extensive TDP-43 proteinopathy, including within the
regions investigated in this study. The determinants of
extent of TDP-43 pathology, of which disease duration
does not appear to be one, therefore remain unclear.
Age has been suggested as a negative prognostic factor
in ALS, but our analysis shows this was not a determinant
of the extent of TDP-43 pathology. Immune dysregulation
may play a role as patients with “rapidly progressive” ALS
have a reduction in regulatory T-lymphocytes and reduc-
tion in transcription factors required for the function of
this T-cell population (i.e., FoxP3) [47]. This suggests the
intriguing possibility that short-lived patients with im-
mune dysregulation may be among those with widespread
TDP-43 deposition and rapid progression. Lastly, the sig-
nificant association of basal forebrain and hypothalamic
pathology with bulbar symptoms at onset identified here
suggests the possibility that the site of disease initiation
may play an important role in the propagation and final
extent of disease. These and other factors that influence
the kinetics and extent of TDP-43 spread are poorly
understood and are deserving of further investigation.Study limitations
There are limitations of the present study due to the
retrospective design. First, the study was conducted with
archived sections available or with supplemental sections
that could be generated from stored tissues. In rare
instances, involving older archived cases, one or more
anatomic regions were not available in the original ma-
terial and no additional tissue was available for sampling.
Prospective sampling in future ALS cases will ensure
more uniformity in the anatomic regions available for
assessment. Based on our findings, two sections are
likely to yield the most valuable pathologic data for fu-
ture studies. The first, inclusive of basal forebrain, could
be taken at level of the optic chiasm, anterior commissure,
septal area, and BNST, and would demonstrate LSA,
BNST, VS/Is, VP, and rostral hypothalamus (Figure 1A).
The second, inclusive of tuberal and caudal hypothalamus,
could be taken at the level of the tuber cinereum and for-
nix and would demonstrate LHA/TMN, portions of MB,
LTN, periventricular nuclei of the tuberal region including
VMH, and the PHA (Figure 1B). Standardized sections
across many non-ALS and ALS patients would also allow
for more precise stereological analysis to determine the
extent of neuronal loss, which is difficult to estimate by
H&E and TDP-43 stains.
The ability to determine the clinical sequelae of the
pathology described herein is also limited by the retro-
spective nature of the study. Future clinicopathologic
studies of these clinical features with respect to the brain
regions identified here will further clarify the importance
of these pathologic findings in the extra-motor manifes-
tations of ALS. This is particularly true with respect to
measures of energy metabolism. The optimal clinical
measures would include careful documentation of BMI
at multiple time points [7] and measured resting energy
expenditure [42] as calculated resting energy expend-
iture underestimates the hypermetabolism observed in
ALS patients [43]. The pathologic findings documented
herein provide a basis for the closer examination of these
clinical measures with respect to TDP-43 pathology.
Conclusions
This study has demonstrated that a subset of patients
with ALS have TDP-43 pathology within basal forebrain
and hypothalamus, which may contribute to the extra-
motor symptoms of the disease, including alterations in
energy metabolism, autonomic nervous system dysfunc-
tion, and frontal executive dysfunction. The pathologic
involvement was fairly stereotypic, and in nearly all cases
pathologic involvement of forebrain components (VS/Is,
BNST, medium-sized neurons of SI) preceded hypothal-
amic involvement (LHA/TMN, MB/LTN). Basal fore-
brain and hypothalamic pathology was associated with
the presence of other non-canonical TDP-43 inclusion
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Finally, the presence of forebrain/hypothalamic pathology
was associated with bulbar onset of disease, which suggests
the possibility of a unique and previously unrecognized
clinico-pathological relationship in ALS.
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